The drug was already being used in trials of TSC patients in England, but only to test its efficacy against kidney and lung lesions, also associated with the disorder. Cambridge's de Vries, who is running those trials, said that until recently, most scientists hadn't expected the drug to work on cognitive problems because those had been thought to result from growths in the brain.